ER
JAZZ icon

Enlightenment Research’s Jazz Pharmaceuticals JAZZ Stock Holding History

Enlightenment Research’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-300
Closed -$37K – 380
2018
Q4 		$37K Buy
+300
New +$44.5K 0.05% 331

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Enlightenment Research's JAZZ Position: Q1 2019 in Review

Enlightenment Research sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 300 shares — an estimated $37K sold.

Enlightenment Research first reported a position in JAZZ in Q4 2018 and held it in 1 quarter. The position peaked at $37K in Q4 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • Enlightenment Research reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 300 Jazz Pharmaceuticals shares in Q1 2019, an estimated $37K.
  • Enlightenment Research first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Jazz Pharmaceuticals position peaked at $37K in Q4 2018.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.